|Videos|July 6, 2023
Fixed-Dose Capecitabine in Metastatic Breast Cancer: The X-7/7 Trial
The Oncology Brothers, joined by Stephanie Graff, MD, FACP, share their thoughts on data from the X-7/7 trial of fixed-dose capecitabine in patients with metastatic breast cancer.
Advertisement
Advertisement
Related to this article
Giredestrant plus everolimus reduced the risk of progression or death by 44% in the ITT population and 62% in ESR1-mutated disease in phase 3 evERA data published in NEJM.
Elinzanetant, already approved for menopause-related VMS, is being considered to address hot flashes associated with adjuvant breast cancer endocrine therapy.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
What Stood Out at IMS 2026? Five Myeloma Experts Weigh In
2
Ubamatamab Shows Durable Responses in Low-Grade Serous Ovarian Cancer
3
Pirtobrutinib Gains FDA Approval for Frontline CLL/SLL in Select Patients
4
Giredestrant Plus Everolimus Improves PFS in ER+ Advanced Breast Cancer
5